XRTX | XORTX Therapeutics Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.2225 - 1.2750
52 Week Range	1.0900 - 7.00
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	2,681
Average Volume	85,596
Shares Outstanding	3,223,565
Market Cap	3,964,985
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-09-23

Valuation
Profitability
Growth
Health
P/E Ratio	10.25
Forward P/E Ratio	N/A
EPS	0.12
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	2
Country	Canada
Website	XRTX

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

XRTX's peers: CNTX, NRSN, BTTX, QNRX, ENSC

*Chart delayed

Analyzing fundamentals for XRTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is very weak. For more detailed analysis please see XRTX Fundamentals page.

Watching at XRTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on XRTX Technicals page.